Dr Schalkwijk is a pharmacist by training and obtained his BSc in Pharmaceutical Sciences and a PharmD from Utrecht University. He holds a PhD in Clinical Pharmacology and Applied Pharmacometrics from Radboud University Medical Center, The Netherlands. His PhD was focused on the antiretroviral quantitative clinical pharmacology in HIV-infected pregnant women. Dr Schalkwijk has contributed to over 20 peer-reviewed articles in journals.
Dr Schalkwijk is a Clinical Pharmacometrician in the department of Quantitative Clinical Pharmacology at AstraZeneca. He has responsibility for translational modelling, population PK, PKPD, exposure-response, disease modelling, and simulations to inform and support data interpretation and decision making across all clinical development phases in oncology. Currently, Dr Schalkwijk is involved in late-phase development of a Phase 3 asset to treat EGFRm non-small cell lung cancer, as well as a new drug application (NDA) for a pediatric orphan indication.
